Comparative Pharmacology
Head-to-head clinical analysis: HARLIKU versus MEPSEVII.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HARLIKU versus MEPSEVII.
HARLIKU vs MEPSEVII
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.
MEPSEVII (vestronidase alfa) is a recombinant form of human beta-glucuronidase that hydrolyzes accumulated glycosaminoglycans (GAGs) in lysosomes, restoring enzymatic activity in patients with Mucopolysaccharidosis VII (Sly syndrome).
1 mg orally once daily.
1 mg/kg administered intravenously once weekly over 4 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; permits twice-daily dosing. Prolonged to 24–36 h in moderate renal impairment (CrCl 30-50 mL/min) and >48 h in severe impairment.
Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
Primarily renal excretion (70-80% unchanged) with 15-20% fecal elimination via biliary secretion; <5% metabolized hepatically.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Category C
Category C
Unknown
Unknown